Cantor Fitzgerald Assumes Cidara Therapeutics (CDTX) at Overweight, Sees Underappreciated Sales Potential
Tweet Send to a Friend
Cantor Fitzgerald assumes coverage on Cidara Therapeutics (NASDAQ: CDTX) with a Overweight rating and a price target of $15.00.Analyst Louise ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE